Search for Clinical Trial Results

Sponsored By

Scleroderma, Diffuse - 20 Studies Found

Status Study
Completed Study Name: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Date: 2007-01-29
Interventions: Drug: N-acetylcysteine (NAC)
Recruiting Study Name: Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Condition:
  • Scleroderma, Diffuse
  • Diffuse Cutaneous Sy
    Date: 2015-06-30
    Interventions:
    • Drug: IVA337 Capsules of 200mg
Recruiting Study Name: Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Date: 2012-08-01
Terminated Study Name: Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Condition: Scleroderma, Systemic
Date: 2007-01-03
Interventions:
  • Drug: Thalidomide Thalidomide

Completed Study Name: Nilotinib in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Date: 2010-07-01
Interventions: Drug: Nilotinib (Tasigna) Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
Active, not recruiting Study Name: Taking Charge of Systemic Sclerosis
Condition: Scleroderma
Date: 2015-05-22
Interventions:
  • Other: Internet-based self-management program
Completed Study Name: Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Condition: Scleroderma
Date: 2013-01-04
Interventions: Other: Followup survey
Completed Study Name: Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Date: 2007-11-07
Interventions: Drug: Imatinib Mesylate In initial phase, patients will be treated with Gleevec 400 mg daily for 12 mont
Completed Study Name: Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Date: 2008-04-25
Recruiting Study Name: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Condition: Scleroderma
Date: 2012-06-18
Interventions: Drug: Campath Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the incl
Next >>>